Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys

Acta Pharmacologica Sinica

Volumn 26, Issue 1, 2005, Pages 124-128

  Song, Hai Feng ^a   Liu, Xiu Wen ^a   Zhang, Hai Ning ^a   Zhu, Bao Zhen ^a   Yuan, Shou Jun ^a   Liu, Shang Yi ^a   Tang, Zhong Ming ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Endostatin; Immunoenzyme techniques; Macaca mulatta; Pharmacokinetics

Indexed keywords

ENDOSTATIN; HISTIDINE; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME IMMUNOASSAY; ESCHERICHIA COLI; MULTIPLE DRUG DOSE; NONHUMAN; RHESUS MONKEY; SINGLE DRUG DOSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ENDOSTATINS; HISTIDINE; INJECTIONS, INTRAVENOUS; MACACA MULATTA; OLIGOPEPTIDES; RECOMBINANT PROTEINS;

EID: 11844277637     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00009.x     Document Type: Article

References (13)

1. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17: 4249-56.
2. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
3. Beohm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
4. Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 2000; 25: 97-101.
5. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertie AL, Zorick T, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001; 61: 7375-8.
6. Maio M, Altomonte M, Calabro L, Fonsatti E. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies. Front Biosci 2001; 6: D776-84.
7. Ryan CJ, Wilding G. Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging 2000; 17: 249-55.
8. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001; 7: 3366-74.
9. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, Huang N, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 2001; 61: 478-81.
10. Hengen P. Purification of His-Tag fusion proteins from Escherichia coli. Trends Biochem Sci 1995; 20: 285-6.
11. Tallet B, Astier-Gin T, Castroviejo M, Santarelli X. One-step chromatographic purification procedure of a His-tag recombinant carboxyl half part of the HTLV-I surface envelope glycoprotein overexpressed in Escherichia coli as a secreted form. J Chromatogr B Biomed Sci Appl 2001; 753: 17-22.
12. Gibert S, Bakalara N, Santarelli X. Three-step chromatographic purification procedure for the production of a his-tag recombinant kinesin overexpressed in E. coli. J Chromatogr B Biomed Sci Appl 2000; 737: 143-50.
13. Huang YW, Lu ML, Qi H, Lin SX. Membrane-bound human 3beta-hydroxysteroid dehydrogenase: overexpression with His-tag using a baculovirus system and single-step purification. Protein Expr Purif 2000; 18: 169-74.